Faculty

Jody C. Olson, M.D.

Clinical Studies

Chronic Liver Disease Evolution and Registry for Event and Decompensation (CLEARED) Global Study of Liver Disease Outcomes in Inpatients (CLEARED) Rochester, Minn., Scottsdale/Phoenix, Ariz.
The purpose of this study is to evaluate the outcome of hospitalization related to the presence of cirrhosis. We are participating in optional blood, saliva, urine, ascitic fluid and stool collection.

A Phase 1 Prospective Study of the Miromatrix External Liver Assist Product (miroliverELAP®) for Liver Support in Adults With Acute Liver Failure. Rochester, Minn. The clinical trail will assess the safety of miroliverELAP for the treatment of acute liver failure without underlying chronic liver disease. miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver graft and an extracorporeal blood circuit. miroliverELAP Is intended to support the native (failed) liver for up to 48-hours of continuous treatment to allow time for liver recovery or to identify a transplantable liver.

Chronic Liver Disease Evolution and Registry for Event and Decompensation (CLEARED) Global Study of Liver Disease Outcomes in Inpatients (CLEARED) Jacksonville, Fla.
The purpose of this study is to evaluate the outcome of hospitalization related to the presence of cirrhosis. We are participating in optional blood, saliva, urine, ascitic fluid and stool collection.
Patient Preference for an Implantable Device to Treat Liver Ascites Rochester, Minn., Scottsdale/Phoenix, Ariz.
The puropose of this study is to utilize a discrete-choice experiment (DCE) survey to elicit benefit-risk preferences for interventional treatment attributes in patients with refractory or recurrent ascites due to liver cirrhosis.